<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02617121</url>
  </required_header>
  <id_info>
    <org_study_id>HallymUMC</org_study_id>
    <nct_id>NCT02617121</nct_id>
  </id_info>
  <brief_title>The Effects of Gabapentin and Ramosetron on Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgery</brief_title>
  <acronym>PONV</acronym>
  <official_title>Comparison of the Prophylactic Anti-emetic Efficacy of Gabapentin and Ramosetron in Patients Undergoing Laparoscopic Gynecological Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hallym University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to compare the effects of gabapentin and ramosetron on PONV in
      patients undergoing laparoscopic gynecologic surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative nausea and vomiting (PONV) in the postanesthesia care unit is a common
      occurrence after general anesthesia. And laparoscopic gynecological surgery is associated
      with a high incidence of PONV. Several antiemetic agents such as dopaminergic, histaminic and
      5-HT3 antagonist (including ondansetron, ramosetron, granisetron) have been used to prevent
      PONV. Gabapentin, anti-convulsant, has been shown to decrease PONV, as well as chemotherapy
      induced nausea and vomiting in recent studies, although the exact mechanism against PONV is
      not known. The purpose of this study was to compare the efficacy of gabapentin and ramosetron
      in preventing PONV in patients undergoing laparoscopic gynecological surgery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of postoperative nausea and vomiting</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>The incidence of postoperative nausea and vomiting will be assessed during 48 hours after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of nausea</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>The severity of nausea will be assessed using verbal rating scales (VRS 11-points scales: 0=no nausea to 10=nausea as bad as it could be)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain score</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>The pain score will be assessed using verbal rating scales (VRS 11-points scales: 0=none to 10=most severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sedation score</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>The sedation score will be assessed using verbal rating scales (VRS 11-points scales:0=none to 10=most severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient's overall satisfaction score</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>The patient's overall satisfaction score will be assessed using 5 point scales (5=very satisfied, 4=somewhat satisfied, 3=neither satisfied nor dissatisfied, 2=somewhat dissatisfied, 1=very dissatisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>The side effects such as somnolence, dizziness, headache, tremor, diplopia and nystagmus will be assessed and treated</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral gabapentin 300 mg 1 hours before induction of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ramosetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ramosetron 0.3 mg iv at end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin and ramosetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral gabapentin 300 mg 1 hours before induction of anesthesia ramosetron 0.3 mg iv at end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>oral gabapentin 300 mg 1 hour before induction of anesthesia</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramosetron</intervention_name>
    <description>ramosetron 0.3 mg iv at end of surgery</description>
    <arm_group_label>ramosetron</arm_group_label>
    <other_name>Nasea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin and Ramosetron</intervention_name>
    <description>oral gabapentin 300 mg 1 hour before induction of anesthesia and ramosetron 0.3 mg iv at end of surgery</description>
    <arm_group_label>Gabapentin and ramosetron</arm_group_label>
    <other_name>Neurontin and Nasea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ASA physical status 1 and 2 between 20 and 65 years undergoing
             laparoscopic gynecological surgery with patient-controlled analgesia for postoperative
             pain control.

        Exclusion Criteria:

          -  Pregnant women

          -  Patients who took sedatives, antiemetics, hypnotics, analgesics, steroid, or
             gabapentin

          -  Patients with neurological deficits

          -  Patients with history of drug abuse and allergy of study drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyung Mi Kim, M.D.</last_name>
    <phone>+82-31-380-3945</phone>
    <email>sumsonyo@hallym.or.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Soo Kyung Lee, Ph.D.</last_name>
    <phone>+82-31-380-3945</phone>
    <email>agneta@hallym.or.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>KS009</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2015</study_first_posted>
  <last_update_submitted>November 25, 2015</last_update_submitted>
  <last_update_submitted_qc>November 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
    <mesh_term>Ramosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

